INTRODUCTION
Dasatinib is a dual tyrosine kinase inhibitor designed to target src kinase and the mutated bcr/abl kinase. It is widely used for the treatment of bcr/abl þ leukemias. 1, 2 As a known side effect, patients taking dasatinib may develop hyperleukocytosis with a predominance of CD8 þ T-cells. Furthermore, patients taking dasatinib are prone to severe infections indicating immunosuppressive activity of the drug. 3 In vitro, as well as in murine studies, dasatinib has been shown to suppress effector memory T-cell function by blocking TCR-triggering via inhibition of the src-kinase Lck. [4] [5] [6] [7] [8] [9] Here, we describe a patient after haploidentical SCT for Ph þ ALL, who experienced severe immunosuppression due to dasatinib treatment. Analysis of the patient's serum samples at different time points, as well as comparison of functional immune assays for T-cell activation either in whole blood or in washed PBMC provides evidence for a direct suppressive effect of dasatinib in the serum of this patient.
CASE REPORT
An 8-year-old boy with bcr/abl þ acute lymphatic leukemia in third morphologic remission following reinduction with daunoxome, fludarabine, cytarabine and G-CSF was scheduled for haploidentical SCT receiving a T-cell depleted graft from his mother. The conditioning regimen consisted of fludarabine, thiotepa and melphalan using anti-thymocyte globulin as immunosuppression during conditioning. Following transplanation, the patient received no immunosuppressive medication. Eight weeks after SCT, increased copy numbers of bcr/abl transcripts in the BM suggested imminent relapse (minimal residual disease level of bcr/abl 10 À 3 ). Dasatinib treatment (maximum 1 Â 70 mg/m 2 ) in combination with donor lymphocyte infusions (25 000 haploidentical CD3 þ /kg) was initiated (total of five infusions) ( Figure 1 ). Four weeks after initiation of dasatinib treatment, the patient became ill with spiking fever due to CMV and adenovirus reactivation. Chimaerism analysis revealed mixed chimaerism with up to 60% autologous cells. In addition, the patient developed histologyproven EBV-associated post-transplant lymphoproliferative disease in a cervical lymph node. He required emergency treatment with rituximab. Although the patient responded to rituximab and post-transplant lymphoproliferative disease vanished, the patient continued to suffer from therapy-refractory multi-virus disease (CMV, EBV, adenovirus) with spiking fever for over 2 months. This occurred in striking discrepancy to a profound lymphocytosis and a high CD8 T-cell count (up to 4000/uL). Because of this discrepancy, we decided to evaluate the patient's T-cell responses to viral antigens to better understand the immunological events leading to this clinically serious situation.
IMMUNOLOGICAL EVALUATION
The patient's T-cells were functionally tested for cytokine production in response to a CMVpp65 overlapping peptide pool. For comparison, the mother's PBMC (the haploidentical donor) were evaluated. In contrast to the clinically observed inability to control various viruses, at least 10% of the patient's CD8
þ T-cells were reactive against CMV-derived peptides ( Figure 2a ). However, this assay was peformed by activating ficolled PBMC in peptide containing medium. When the peptide mix was added directly to whole blood, the patient's T-cell response was completely abolished ( Figure 2a ). As a control we analyzed the mother's T-cell repertoire and similar percentages of functional peptide specific T-cells were detected regardless of the assay conditions. This data suggested that the patient's serum contained inhibitory factors, whereas the T-cells themselves were fully functional.
To prove this hypothesis, we performed intracellular cytokine staining on PBMC from healthy donors incubating the cells either with 50% patient serum or control serum. T-cell responses were almost completely suppressed when patient serum was present during the incubation phase (Figure 2b ).
Given the observed strong immunosuppression measured ex vivo, we decided to pause dasatinib treatment. The clinical effect was striking, as the patient's fever ended within 72 h and viral clearance was achieved within 1 week. As the patient . Maximum copy number for CMV was 410/mL (d140), for ADV 6000/mL (d130) and for EBV 20 000/mL (d100). DLI were given as 25 000 CD3 þ T-cells/kg at the indicated time points (arrows). The time points t1 and t2 for immunological testing are indicated as triangles at the bottom of the x-axis. received a multitude of drugs, these may all have interacted with the assay. We, therefore, tested a serum sample from the intial time point in parallel with a sample drawn 6 days after cessation of dasatinib treatment: in contrast to the initial serum, there was no sign of immunosuppressive activity in the serum sample taken 6 days after cessation of dasatinib treatment (comedication remained unchanged) (Figure 2c ). Titrating dasatinib to CMV-specific T-cells derived from a healthy donor during the activation process confirmed that dose levels in the nM-range, which can be reached in patients, 10 are in fact suppressive for T-cell function (2d).
DISCUSSION
The clinical course of this patient is striking, as cessation of dasatinib lead to prompt clearance of all three viruses. The increase in the autologous fraction (up to 60%) correlated with CD8 dominant lymphocytosis during dasatinib treatment. Why this Serum-mediated inhibition of T-cell activation: testing of PBMC from a healthy donor for reactivity to the pp65 peptide pool. PBMC were stimulated for 5 h in the presence of 50% serum from the patient, which was taken either when still on dasatinib (t1 ¼ d134) or off dasatinib 6 days later (t2 ¼ d140). (c) Restored T-cell function after cessation of dasatinib: whole blood assay using the patient's blood when still on dasatinib (t1) or 6 days after cessation of dasatinib (t2) at the time of viral clearance. Stimulation for 5 h with a peptide pool spanning the CMV protein pp65. For all experiments similar results were obtained when using the CEF (CMV/Flu/EBV) peptide pool. (d) Direct suppressive effect of dasatinib on effector memory function. A T-cell line against the CMV-specific, HLA-A2-restricted peptide epitope pp65(495-504) was generated from a healthy donor as described previously. 12 Cells were restimulated with peptide-pulsed, autologous GM-CSF/IL4-activated monocytes in the presence of titrated amounts of dasatinib. Intracellular cytokine production was assessed by flow cytometry after 5 h of incubation in the presence of brefeldin A.
fraction dropped already before dasatinib cessation remains unclair. Remarkably imminent relapse (bcr/abl at the level of 10 À 3 at the time of start of dasatinib treatment) of the ALL early after transplant-leaving few therapeutic options-could be prevented. The patient became bcr/abl negative and dasatinib was reintroduced in a reduced dose (20 mg daily). Ten months after transplantation the patient was MRD negative and returned to his home country.
The patient described here took dasatinib at a standard dosage once daily. Other studies report on clinical signs of immunosuppression with a similar dosage, however drug levels in the serum have not been assessed in these studies. 3, 11 We tried to determine the dasatinib serum level by HPLC, but were unsuccessful due to drug interference with the comedication. Thus, we cannot rule out the possibility that this patient may have had a higher drug serum level due to interactions with drugs required as therapy/ prophylaxis after haploidentical transplantation.
Immunosuppression is one of the known side effects of dasatinib treatment. 3 In vitro the suppressive mechanism of dasatinib could be identified as blockade of TCR-triggering via inhibition of Lck-phosphorylation. 7, 8 However, there are only a few studies that assess T-cell function in whole blood assays. 3, 11 Our data highlight the discrepancy that may occur when functional assays are performed on ficolled PBMC rather than in whole blood or patient serum containing medium. We suggest functional assays based on whole blood to provide better diagnostic clues when assessing T-cell immunity after transplantation.
